Browse
Submit Data
Databases
API
Help

Dataset Information

2 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Discovery of DNA methylation markers in peripheral blood mononuclear cells, innovation of detection technology and application value in early diagnosis of malignant tumors

ABSTRACT: Interventions: breast cancer group:no;colorectal cancer group:no;lung cancer group:no;benign disease group:no;healthy control group:no Primary outcome(s): DNA methylation sites Study Design: Cohort study

DISEASE(S): Breast Cancer, Colorectal Cancer, Lung Cancer

PROVIDER: 82774 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

DNA methylation in the malignant transformation of meningiomas

2013-01-10 | GSE42882 | GEO

DNA methylation in the malignant transformation of meningiomas

Project description:Genome wide DNA methylation profiling of malignant, atypical and benign meningiomas samples. The Illumina infinium HumanMethylation450 beadchip kit was used, which assayed 450,000 potential methylation sites. Bisulphite converted DNA from the 23 samples were hybridised to the Illumina Infinium 450 Human Methylation Beadchip.

2013-01-10 | E-GEOD-42882 | biostudies-arrayexpress

The DNA methylomes of serous borderline tumours reveal subgroups with malignant-like or benign-like profiles

Project description:Serous borderline tumours (SBOT) are a challenging group of ovarian tumours positioned between benign and malignant disease. We have profiled the DNA methylomes of 12 low grade serous carcinoma (LGSC), 19 SBOT and 16 benign serous tumours (BST) across 27,578 CpG sites to further characterise the epigenomic relationship between these subtypes of ovarian tumours. Unsupervised hierarchical clustering of DNA methylation levels showed that LGSC differ distinctly from BST, however, not from SBOT. Gene ontology analysis of genes showing differential methylation at linked CpG sites between LGSC and BST revealed significant enrichment of gene groups associated with cell adhesion, cell-cell signalling and the extracellular region consistent with a more invasive phenotype of LGSC as compared to BST. Consensus clustering highlighted differences between SBOT methylomes and returned subgroups with malignant-like or benign-like methylation profiles. Furthermore, a two loci DNA methylation signature can distinguish between these SBOT subgroups with benign-like and malignant-like methylation characteristics. Our findings indicate striking similarities between SBOT and LGSC methylomes which supports a common origin and the view that LGSC may arise from SBOT. A subgroup of SBOT can be classified into tumours with a benign-like or a malignant-like methylation profile which may help in identifying tumours more likely to progress into LGSC.

2012-12-31 | GSE40105 | GEO

Methylation profiles of benign and malignant bone tumorus

Project description:Methylation profiles of benign and malignant bone tumorus

| PRJNA489284 | ENA

the study of the diagnostic value of DNA methylation in blood and stool in colorectal cancer

Project description:Interventions: Gold Standard:Colonoscopy biopsy;Index test:detection of novel DNA methylation sites in stool and blood Primary outcome(s): Deoxyribonucleic acid methylation status and blood Study Design: Sequential

| 2716875 | ecrin-mdr-crc

The DNA methylomes of serous borderline tumours reveal subgroups with malignant-like or benign-like profiles

2012-12-31 | E-GEOD-40105 | biostudies-arrayexpress

Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation Assay

Project description:Epigenomics is developing a colon cancer screening assay based on differential methylation of specific CpG sites for the detection of early stage disease. A genome-wide methylation analysis and oligonucleotide array study using DNA from various stages of colon cancer and normal tissue have been completed to obtain candidate CpG markers. Based on results obtained in the above studies, Epigenomics has moved to the final stages of feasibility with a specific, highly sensitive real-time marker assay that is able to detect colon cancer DNA in blood plasma.

| 2056787 | ecrin-mdr-crc

DNA methylation profiling of malignant pleural mesothelioma

Project description:Diagnosis of malignant pleural mesothelioma (MPM) is a challenging task because of its overlap with other neoplasms or even reactive conditions. Recently, DNA methylation analysis proved to be an effective tool for tumor diagnosis. We thus set out to test this approach for MPM diagnosis. A discovery (n=33) and an independent validation cohort (n=46) of MPM samples were subjected to array-based DNA methylation analyses and their DNA methylation patterns were compared to a representative set of both malignant and benign diagnostic mimics. By both unsupervised hierarchical clustering and t-distributed stochastic neighbor embedding analysis, MPM samples of the discovery cohort exhibited a distinct DNA methylation profile, different from that of other neoplastic and reactive mimics.

2021-03-20 | GSE164269 | GEO

Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors

Project description:Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors

| EGAS00001006205 | EGA

Array-CGH of malignant peripheral nerve sheath tumors (MPNST)

Project description:Comparison of copy number changes in MPNST samples against benign neurofibromas in NF1 patients

2009-05-20 | GSE16041 | GEO